Journal of psoriasis and psoriatic arthritis · 2026

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.

СтатьяНазвание и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Mazzanti Camilla, Paroli Marino, Santoboni Gianluca, Addimanda Olga, Raffeiner Bernd, Bezzi Alessandra, Visalli Elisa, Celletti Eleonora, Farina Antonella, Bernardi Simone, Larosa Maddalena, Andracco Romina, Del Medico Patrizia, Colella Molica Aldo Biagio, Giuggioli Dilia, Lumetti Federica, Sandri Gilda, Priora Marta, Serale Francesca, Nucera Valeria, Ometto Francesca, Bravi Elena, Lo Gullo Alberto, Scolieri Palma, Parisi Simone, Ravagnani Viviana, Vitetta Rosetta, Marchetta Antonio, Becciolini Andrea, Angrisani Claudio, De Simone Massimiliano, Caccavalle Rosalba, Reta Massimo, Magnani Mirco, Mascella Fabio, Foti Roberta, Amato Giorgio, De Lucia Francesco, Dal Bosco Ylenia, Foti Rosario, Di Penta Myriam, Sabatini Emanuela, Del Biondo Pietro, Girelli Francesco, Camellino Dario, Bianchi Gerolamo, Mansueto Natalia, Smerilli Gianluca, Franchina Veronica, Salvarani Carlo, Ianniello Aurora, Giampietro Cecilia, Di Donato Eleonora, Santilli Daniele, Lucchini Gianluca, Arrigoni Eugenio, Platè Ilaria, Bruzzese Vincenzo, Fusaro Enrico, Ditto Maria Chiara, Murgia Davide, Rovera Guido, Volpe Alessandro, Ferrero Giulio, Adorni Giuditta, Colella Molica Francesco, Ariani Alarico

Аннотация

We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We emphasize the importance of persistence, as assessed through the Drug Retention Rate (DRR), a validated measure in observational studies of biologic therapies. The DRR reflects a complex interplay of factors, including efficacy, safety, and patient choice, making it a valuable indicator of therapeutic performance. We agree that adherence is an interesting topic, but argue that its absence does not invalidate persistence data. Our study was designed to evaluate treatment persistence, not behavioural pharmacology. We believe that our methodological rigor, real-world design, and consistency with international literature make our data a reliable reference for understanding ixekizumab persistence in routine clinical pratice.

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.

Ошибки и ограничения

Аннотация